The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IBIO | -30.28% | -99.82% | -71.67% | -100% |
| S&P | +14.39% | +76.41% | +12.02% | +448% |
iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.
Pre-clinical successes lead to exclusive licensing agreements for iBio.
Investors are excited about the company's new coronavirus vaccine program.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | -100.0% |
| Gross Profit | -$241.00K | -197.5% |
| Gross Margin | -189.00% | 0.0% |
| Market Cap | $43.40M | 93.6% |
| Market Cap / Employee | $2.17M | 0.0% |
| Employees | 20 | 5.3% |
| Net Income | -$8,993.00K | -106.1% |
| EBITDA | -$6,704.00K | -62.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $28.67M | 308.7% |
| Accounts Receivable | $0.00K | 0.0% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.93M | -37.5% |
| Short Term Debt | $518.00K | -51.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -57.47% | -6.4% |
| Return On Invested Capital | -77.16% | -17.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5,757.00K | -48.8% |
| Operating Free Cash Flow | -$5,241.00K | -35.5% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.65 | 0.67 | 1.08 | 0.70 | -41.48% |
| Price to Sales | 105.72 | 31.33 | 87.72 | 637.76 | 968.94% |
| Price to Tangible Book Value | 4.73 | 1.46 | 1.99 | 0.79 | -53.48% |
| Enterprise Value to EBITDA | -8.39 | -1.52 | 0.43 | -21.04 | 346.33% |
| Return on Equity | -90.8% | -101.5% | -54.5% | -70.2% | -43.04% |
| Total Debt | $3.87M | $3.51M | $3.29M | $2.45M | -40.99% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
